NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), Molina Healthcare, Inc. (NYSE: MOH), Skye Bioscience, Inc. (NASDAQ: SKYE), and Perrigo Company plc (NYSE: PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ)

• Class Period: May 28, 2025 to August 29, 2025
  
• Lead Plaintiff Deadline: December 1, 2025
  
• According to the complaint, after reorganization due to bankruptcy on April 29. 2025, Spirit’s common stock was approved for listing on the NYSE under the ticker symbol “FLYY.“ Plaintiff alleges that during the class period, defendants failed to disclose that (i) Spirit was at substantial risk of being unable to meet certain of its debt and other financial obligations; (ii) Spirit was also at substantial risk of being forced to file for Chapter 11 bankruptcy protection within a mere matter of months; and (iii) accordingly, defendants had overstated enhancements to Spirit’s financial condition, liquidity, and overall business and operations, while simultaneously downplaying the negative impacts of adverse market conditions on the same.
  
• On August 29, 2025, Spirit issued a press release disclosing that “the Company has filed voluntary petitions for Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York” and that “[t]he [Company’s] shares are expected to be cancelled and have no value as part of Spirit’s restructuring.” On the next trading day, September 2, 2025, the NYSE suspended trading of Spirit’s common stock. Following the foregoing disclosures and developments, Spirit’s stock price fell $0.71 per share, or 58.2%, to close at $0.51 per share on September 3, 2025—the first day that the Company’s common stock began trading on the over-the-counter (“OTC”) market under the ticker symbol “FLYYQ.”
  
• For more information on the Spirit lawsuit go to: https://bespc.com/cases/FLYYQ
  
  

Molina Healthcare, Inc. (NYSE: MOH)

• Class Period: February 5, 2025 to July 23, 2025
  
• Lead Plaintiff Deadline: December 2, 2025
  
• The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
  
• For more information on the Molina lawsuit go to: https://bespc.com/cases/MOH
  
  

Skye Bioscience, Inc. (NASDAQ: SKYE)

• Class Period: November 4, 2024 to October 3, 2025
  
• Lead Plaintiff Deadline: January 16, 2026
  
• Throughout the Class Period, Defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) nimacimab was less effective than Defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
  
• On October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab[.]” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”
  
• On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.
  
• For more information on the Skye class action go to: https://bespc.com/cases/SKYE
  
  

Perrigo Company plc (NYSE: PRGO)

• Class Period: February 27, 2023 to November 4, 2025
  
• Lead Plaintiff Deadline: January 16, 2026
  
• According to the complaint, during the class period, defendants failed to disclose: (1) that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs; (2) that Perrigo needed to make substantial capital and operational expenditures above the Company’s outwardly stated cost estimates to remediate the infant formula business; (3) that there were significant manufacturing deficiencies in the facility for the Company’s infant formula business; and (4) that, as a result of the foregoing, the Company’s financial results, including earnings and cash flow, were overstated.
  
• Plaintiff alleges that on November 5, 2025, Perrigo announced disappointing financial results for the third quarter ended September 27, 2025. The press release revealed that Perrigo had slashed its fiscal year 2025 outlook “due primarily to infant formula industry dynamics.” The same day, Perrigo issued a press release, announcing the Company “is initiating a strategic review of its infant formula business.” The press release revealed Perrigo is “reassessing the Company’s previously announced investment in this business of $240 million” and that the infant formula business had become “less strategic.” On this news, Perrigo’s stock price fell $5.09, or 25.2%, to close at $15.10 per share on November 5, 2025.
  
• For more information on the Perrigo class action go to: https://bespc.com/cases/PRGO
  
  

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com